INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,789,515 | +13.2% | 130,342 | +37.5% | 0.08% | -1.2% |
Q2 2023 | $6,000,267 | +29.2% | 94,761 | +10.5% | 0.08% | +25.0% |
Q1 2023 | $4,642,767 | +15.7% | 85,739 | +13.1% | 0.06% | +1.6% |
Q4 2022 | $4,013,506 | +24.2% | 75,841 | -45.3% | 0.06% | +70.3% |
Q3 2022 | $3,230,227 | -45.6% | 138,712 | +33.3% | 0.04% | -68.4% |
Q2 2022 | $5,938,000 | -45.1% | 104,036 | -41.2% | 0.12% | -10.0% |
Q1 2022 | $10,818,000 | -15.2% | 176,801 | -27.4% | 0.13% | +42.9% |
Q4 2021 | $12,751,000 | +99.5% | 243,600 | +42.1% | 0.09% | +65.5% |
Q3 2021 | $6,391,000 | +78.3% | 171,440 | +95.2% | 0.06% | +66.7% |
Q2 2021 | $3,585,000 | +56.6% | 87,817 | +30.2% | 0.03% | +26.9% |
Q1 2021 | $2,289,000 | +6.7% | 67,457 | 0.0% | 0.03% | +36.8% |
Q4 2020 | $2,145,000 | -90.4% | 67,457 | -89.6% | 0.02% | -95.3% |
Q4 2019 | $22,277,000 | +2425.7% | 649,300 | +449.8% | 0.40% | +1587.5% |
Q3 2019 | $882,000 | +94.3% | 118,091 | +237.4% | 0.02% | +84.6% |
Q2 2019 | $454,000 | – | 35,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |